 Home > Active Ingredient News > Study of Nervous System > Express Antisense oligonucleotide drugs have reached the end of clinical phase 3 and are scheduled to submit a listing application this year

Express Antisense oligonucleotide drugs have reached the end of clinical phase 3 and are scheduled to submit a listing application this year

 Last Update: 2022-09-14
 Source: Internet
 Author: User

▎ WuXi AppTec content team editor

Ionis Pharmaceuticals and AstraZeneca today jointly announced positive results

ATTRv-PN is a serious, progressive, and life-threatening disease

Eplontersen is an antisense oligonucleotide drug under investigation that uses the antisense oligonucleotide ligand coupling (LICA) technique to conjugate ASO drugs with ligand molecules that bind to specific receptors on the cell surface

NEURO-TTRansform is a global, randomized, open-label clinical Phase 3 trial to test the efficacy and safety

An interim analysis of the 35-week trial showed that eplontersen resulted in an 81.

Eplontersen demonstrates good safety and drug resistance

"The eye-catching data from NEURO-TTRansform shows that eplontersen has a positive effect

References:[1] Ionis presents positive results from Phase 3 NEURO-TTRansform study at International Symposium on Amyloidosis.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Sodium bromide airuike

CAS No.: 7647-15-6

Industrial Grade

$10/KG EXW

Brivaracetam357336-20-0

CAS No.: 357336-20-0

API Grade

$100/KG EXW

Quetiapine fumarate CAS 111974-72-2

CAS No.: 111974-72-2

Pharmaceutical Grade

$100/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.